ERα36-High Cancer-Associated Fibroblasts as an Unfavorable Factor in Triple-Negative Breast Cancer

被引:5
作者
Nagel, Anna [1 ]
Popeda, Marta [1 ]
Muchlinska, Anna [1 ]
Sadej, Rafal [2 ]
Szade, Jolanta [3 ]
Zielinski, Jacek [4 ]
Skokowski, Jaroslaw [4 ,5 ]
Niemira, Magdalena [6 ]
Kretowski, Adam [6 ]
Markiewicz, Aleksandra [1 ]
Zaczek, Anna J. [1 ]
机构
[1] Med Univ Gdansk, Intercollegiate Fac Biotechnol, Lab Translat Oncol, PL-80211 Gdansk, Poland
[2] Med Univ Gdansk, Intercollegiate Fac Biotechnol, Lab Mol Enzymol & Oncol, PL-80211 Gdansk, Poland
[3] Med Univ Gdansk, Dept Pathomorphol, PL-80211 Gdansk, Poland
[4] Med Univ Gdansk, Dept Surg Oncol, PL-80211 Gdansk, Poland
[5] Med Univ Gdansk, Dept Med Lab Diagnost Biobank Fahrenheit BBMRI Pl, Debinki St 7, PL-80211 Gdansk, Poland
[6] Med Univ Bialystok, Clin Res Ctr, PL-15276 Bialystok, Poland
关键词
cancer-associated fibroblasts; breast cancer; estrogen receptor alpha 36; triple-negative breast cancer; ESTROGEN-RECEPTOR-ALPHA; TUMOR; EXPRESSION; CYTOKINES; MICROENVIRONMENT; MYOFIBROBLASTS; SURVIVAL; PROMOTE; GROWTH; ROLES;
D O I
10.3390/cancers14082005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary The tumor microenvironment, as an important constituent of neoplastic tissue, has been a promising target for cancer therapy. Triple-negative breast cancer accounts for around 10-20% of invasive breast cancers. This study describes a new cancer-associated fibroblast subtype characterized by high ER alpha 36 levels that secretes HGF, which can impact triple-negative breast cancer. The data enlighten the importance of the stromal effect on the disease course and underlines the significance of further research on the tumor microenvironment and its role in the progression of cancer. Background: Cancer-associated fibroblasts (CAFs) are the most abundant cell type in the tumor microenvironment (TME). Estrogen receptor alpha 36 (ER alpha 36), the alternatively spliced variant of ER alpha, is described as an unfavorable factor when expressed in cancer cells. ER alpha can be expressed also in CAFs; however, the role of ER alpha 36 in CAFs is unknown. Methods: Four CAF cultures were isolated from chemotherapy-naive BC patients and characterized for ER alpha 36 expression and the NanoString gene expression panel using isolated RNA. Conditioned media from CAF cultures were used to assess the influence of CAFs on triple-negative breast cancer (TNBC) cells using a matrigel 3D culture assay. Results: We found that ER alpha 36(high) CAFs significantly induced the branching of TNBC cells in vitro (p < 0.001). They also produced a set of pro-tumorigenic cytokines compared to ER alpha 36(low) CAFs, among which hepatocyte growth factor (HGF) was the main inducer of TNBC cell invasive phenotype in vitro (p < 0.001). Tumor stroma rich in ER alpha 36(high) CAFs was correlated with high Ki67 expression (p = 0.041) and tumor-associated macrophages markers (CD68 and CD163, p = 0.041 for both). HGF was found to be an unfavorable prognostic factor in TCGA database analysis (p = 0.03 for DFS and p = 0.04 for OS). Conclusions: Breast cancer-associated fibroblasts represent distinct subtypes based on ER alpha 36 expression. We propose that ER alpha 36(high) CAFs could account for an unfavorable prognosis for TNBC patients.
引用
收藏
页数:17
相关论文
共 50 条
[1]   A CXCL1 Paracrine Network Links Cancer Chemoresistance and Metastasis [J].
Acharyya, Swarnali ;
Oskarsson, Thordur ;
Vanharanta, Sakari ;
Malladi, Srinivas ;
Kim, Juliet ;
Morris, Patrick G. ;
Manova-Todorova, Katia ;
Leversha, Margaret ;
Hogg, Nancy ;
Seshan, Venkatraman E. ;
Norton, Larry ;
Brogi, Edi ;
Massague, Joan .
CELL, 2012, 150 (01) :165-178
[2]   Molecular characterization of the tumor microenvironment in breast cancer [J].
Allinen, M ;
Beroukhim, R ;
Cai, L ;
Brennan, C ;
Lahti-Domenici, J ;
Huang, HY ;
Porter, D ;
Hu, M ;
Chin, L ;
Richardson, A ;
Schnitt, S ;
Sellers, WR ;
Polyak, K .
CANCER CELL, 2004, 6 (01) :17-32
[3]   Fibroblast Subtypes Regulate Responsiveness of Luminal Breast Cancer to Estrogen [J].
Brechbuhl, Heather M. ;
Finlay-Schultz, Jessica ;
Yamamoto, Tomomi M. ;
Gillen, Austin E. ;
Cittelly, Diana M. ;
Tan, Aik-Choon ;
Sams, Sharon B. ;
Pillai, Manoj M. ;
Elias, Anthony D. ;
Robinson, William A. ;
Sartorius, Carol A. ;
Kabos, Peter .
CLINICAL CANCER RESEARCH, 2017, 23 (07) :1710-1721
[4]   Role of HGF in epithelial-stromal cell interactions during progression from benign breast disease to ductal carcinoma in situ [J].
Casbas-Hernandez, Patricia ;
D'Arcy, Monica ;
Roman-Perez, Erick ;
Brauer, Heather Ann ;
McNaughton, Kirk ;
Miller, Samantha M. ;
Chhetri, Raghav K. ;
Oldenburg, Amy L. ;
Fleming, Jodie M. ;
Amos, Keith D. ;
Makowski, Liza ;
Troester, Melissa A. .
BREAST CANCER RESEARCH, 2013, 15 (05)
[5]   Role of ERα36 in membrane-associated signaling by estrogen [J].
Chaudhri, Reyhaan A. ;
Schwartz, Nofrat ;
Elbaradie, Khairat ;
Schwartz, Zvi ;
Boyan, Barbara D. .
STEROIDS, 2014, 81 :74-80
[6]   Function of Akt/PKB signaling to cell motility, invasion and the tumor stroma in cancer [J].
Chin, Y. Rebecca ;
Toker, Alex .
CELLULAR SIGNALLING, 2009, 21 (04) :470-476
[7]   Triple-negative breast cancer: therapeutic options [J].
Cleator, Susan ;
Heller, Wolfgang ;
Coombes, R. Charles .
LANCET ONCOLOGY, 2007, 8 (03) :235-244
[8]   Estrogen Receptor Alpha (ERα)-Associated Fibroblasts Promote Cell Growth in Prostate Cancer [J].
Da, Jun ;
Lu, Mujun ;
Wang, Zhong .
CELL BIOCHEMISTRY AND BIOPHYSICS, 2015, 73 (03) :793-798
[9]   Tumor-stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients [J].
de Kruijf, Esther M. ;
van Nes, Johanna G. H. ;
de Velde, Cornelis J. H. van ;
Putter, Hein ;
Smit, Vincent T. H. B. M. ;
Liefers, Gerrit Jan ;
Kuppen, Peter J. K. ;
Tollenaar, Rob A. E. M. ;
Mesker, Wilma E. .
BREAST CANCER RESEARCH AND TREATMENT, 2011, 125 (03) :687-696
[10]   Treatment of triple negative breast cancer (TNBC): current options and future perspectives [J].
De Laurentiis, M. ;
Cianniello, D. ;
Caputo, R. ;
Stanzione, B. ;
Arpino, G. ;
Cinieri, S. ;
Lorusso, V. ;
De Placido, S. .
CANCER TREATMENT REVIEWS, 2010, 36 :S80-S86